Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 0.80 |
| ▸ | BTK | Q06187 | 16/20 | 0.80 |
| ▸ | TXK | P42681 | 13/20 | 0.80 |
| ▸ | ITK | Q08881 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24467305 | 0.90 | JAK3 (1.00) | JAK3BTKTXKITK | |
| SCHEMBL20161850 | 0.90 | JAK3 (1.00) | JAK3BTKTXKITK | |
| SCHEMBL24467354 | 0.90 | JAK3 (1.00) | JAK3BTKTXKITK | |
| SCHEMBL24467264 | 0.88 | JAK3 (1.00) | JAK3BTKTXKITK | |
| SCHEMBL20161848 | 0.88 | JAK3 (1.00) | JAK3BTKTXKITK | |
| SCHEMBL20161845 | 0.86 | JAK3 (0.78) | JAK3BTKTXKITK | |
| SCHEMBL20161844 | 0.84 | JAK3 (0.78) | JAK3BTKTXKITK | |
| SCHEMBL20161860 | 0.83 | JAK3 (1.00) | JAK3BTKTXKITK | |
| SCHEMBL20161720 | 0.83 | JAK3 (1.00) | JAK3BTKTXKITK | |
| SCHEMBL20161858 | 0.83 | JAK3 (1.00) | JAK3BTKTXKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-3534899-B1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | IL2, NFATC1, IL2RA | JAK3 341/4885BTK 398/4885TXK 201/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | JAK3 341/4885BTK 398/4885TXK 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.